In vitro fertilization (IVF) offers prospective parents the option to select their baby’s sex through pre-implantation genetic testing (PGT). This specialized genetic screening examines an embryo’s sex chromosomes, making it possible to choose the sex of the baby. However, it is crucial to note that PGT is an additional step in the IVF process and is not included in the standard costs.
The practice of sex selection via PGT has sparked considerable debate, particularly when used for non-medical reasons. Critics argue that sex selection could pave the way for selecting other traits, such as eye color, hair color, or height. On the other hand, proponents view it as a manifestation of patient autonomy and reproductive freedom.
Genetic testing is often part of the IVF process, which assists individuals in conceiving when natural methods are not feasible. Although genetic testing can reveal the sex of the embryo, its primary purpose is to identify and mitigate the risk of chromosomal abnormalities that could lead to health issues.
While some prospective parents may choose not to know their embryo’s sex prior to implantation, healthcare professionals are advised to clearly communicate that PGT-A will disclose this information during the informed consent process for genetic testing.
